DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Fischer Medical Ventures Limited — Reply to Clarification- Financial results

NSE 1 hr ago·27 Jul 2026, 7:55 am

Fischer Medical Ventures

Fischer Medical Ventures Limited has submitted a clarification response to the stock exchange regarding its financial results for the quarter ended March 31, 2026. This action was taken to comply with Regulation 33 of the SEBI (LODR) Regulations, which mandates listed companies to disclose specific financial information to ensure transparency for investors.

This disclosure is a routine regulatory requirement that provides the market with updated financial data. For investors, this update helps in monitoring the company's performance and aids in making informed investment decisions based on the latest available information.

Investors should closely review the details of the clarification to understand the company's current financial position. Keeping an eye on future earnings reports and any further regulatory filings will be essential to gauge the company's trajectory.